Barchart.com’s Chart of the Day – AbbVie
Jan 27, 2018: Published by Barchart.com
The Chart of the Day belongs to AbbVie (ABBV). If found the pharmaceutical stock by using Barchart to sort today’s Top Stocks to Own list first by the highest Weighted Alpha, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter issued a buy signal on 11/7 the stock gained 31.13%
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients’ live healthier lives and collaborate on sustainable healthcare solutions.
Barchart’s Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.
Barchart technical indicators:
Weighted Alpha 121.10+
100% technical buy signals
Above its 20, 50 and 100 day moving averages
16 new highs and up 26.05% in the last month
Relative Strength Index 87.49%
Technical support level at 115.85
Recently traded at 123.21 with a 50 day moving average of 98.70
Market Cap $172.90 billion
Dividend yield 2.69%
Revenue expected to grow 9.60% this year and another 10.80% next year
Earnings estimated to increase 1540% this year, an additional 18.50% next year and continue to compound at an annual rate of 14.97% for the next 5 years
Wall Street analysts issued 4 strong buy, 6 buy and 10 hold recommendations on the stock.
Based on 8 analysts offering 12 month price targets for ABBV in the last 3 months. The average price target is $112.88 with a high estimate of $150.00 and a low estimate of $84.00. Analyst Consensus – Moderate Buy.